Furthermore, CPI-613 suppresses the proliferation of multiple myeloma cells by inducing mitochondrial metabolic dysfunction through the targeting of pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) and oxoglutarate dehydrogenase (OGDH), and it produces significant anti-tumor effects when combined with bortezomib at a lower dose [88]. This evidence concerns the gene OGDH and plasma cell myeloma.